3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
14
Carcinoma, Non-Small-Cell Lung
13
Neoplasms
10
Glioblastoma
9
Fallopian Tube Neoplasms
8
Colorectal Neoplasms
8
Breast Neoplasms
8
Lung Neoplasms
7
Rectal Neoplasms
6
Neoplasm Metastasis
6
Gliosarcoma
6
Colonic Neoplasms
6
Carcinoma, Renal Cell
6
Brain Neoplasms
6
Prostatic Neoplasms
4
Melanoma
4
Uterine Cervical Neoplasms
3
Solitary Fibrous Tumor, Pleural
3
Sarcoma, Alveolar Soft Part
3
Sarcoma
3
Mesothelioma, Malignant
3
Carcinoma, Hepatocellular
3
Breast Neoplasms, Male
3
Advanced Solid Tumor
3
Uveal Melanoma
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Leukemia, Myeloid, Acute
2
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
cediranib
×
Clear all
NCT00939848
2014-10-27
ABC-03
University College, London
Phase 2/3
Completed
124 enrolled